1 / 3

Real-world evidence solution market

Global Real-World Evidence Solutions market has gained momentum in recent years with a CAGR of 16.5%, in value terms, over the forecast period 2021-2026, and is expected to reach USD 3321.7 million by 2026.

priyanka25avhad
Download Presentation

Real-world evidence solution market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Real-world evidence solution market

  2. Global Real-World Evidence Solutions market has gained momentum in recent years with a CAGR of 16.5%, in value terms, over the forecast period 2020-2026, and is expected to reach USD 3,321.7 million by 2026. The growth is due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases and delays in drug development, and the subsequent increase in development costs. Besides, the real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others, that helps in the growth of the overall market. Therapeutic segment contributing major share to drive the real-world evidence solution market. Based on the therapeutic area, the real-world evidence market is broadly categorized into oncology, immunology, neurology, cardiovascular disease, and other therapeutic areas the oncology segment has been accounted for the largest share of the real-world evidence market. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

  3. Rising in the investment market to create market opportunities in upcoming years. A rise in investment creates new opportunities in the market. For instance, Syapse, a San Francisco, CA-based provider of precision oncology solutions announced USD 30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine’s Managing Partner Zack Scott, MD will join the Syapse Board of Directors. Syapse collaborates with life sciences companies to provide insights from real-world data through its portfolio of products to support research and product development, clinical trials patient matching, real-world evidence regulatory filings, and monitoring of commercially approved products. Syapse supports health systems with insights to support health systems’ large-scale precision medicine programs through integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions. Read More: https://www.blueweaveconsulting.com/global-real-world-evidence-solutions-market-bwc19297

More Related